Adverse events
| AE . | Grade 1-2 . | Grade 1-2 . | Grade 3-4 . | Grade 3-4 . | Total, N = 90 . |
|---|---|---|---|---|---|
| CLL, N = 28, (%) . | NHL, N = 62, (%) . | CLL, N = 28, (%) . | NHL, N = 62 (%) . | No. of patients (%) . | |
| Anemia | 4 (14) | 13 (21) | 3 (11) | 9 (15) | 29 (32) |
| Thrombocytopenia | 1 (4) | 3 (5) | 2 (7) | 10 (16) | 16 (18) |
| Diarrhea | 3 (11) | 13 (21) | 0 (0) | 0 (0) | 16 (18) |
| Petechiae | 5 (18) | 7 (11) | 1 (4) | 0 (0) | 13 (14) |
| Rash | 6 (21) | 9 (15) | 0 (0) | 1 (4) | 16 (18) |
| Pyrexia | 5 (18) | 5 (8) | 2 (7) | 0 (0) | 12 (13) |
| Nasopharyngitis | 4 (14) | 8 (13) | 0 (0) | 0 (0) | 12 (13) |
| Neutropenia | 0 (0) | 2 (3) | 4 (14) | 5 (8) | 11 (12) |
| Bruising | 6 (21) | 5 (8) | 0 (0) | 0 (0) | 11 (12) |
| Lower respiratory tract infection | 5 (18) | 1 (2) | 1 (4) | 3 (5) | 10 (11) |
| Cough | 4 (14) | 6 (10) | 0 (0) | 0 (0) | 10 (11) |
| Nausea | 2 (7) | 9 (15) | 0 (0) | 0 (0) | 11 (12) |
| Hematoma | 5 (18) | 3 (5) | 1 (4) | 0 (0) | 9 (10) |
| AE . | Grade 1-2 . | Grade 1-2 . | Grade 3-4 . | Grade 3-4 . | Total, N = 90 . |
|---|---|---|---|---|---|
| CLL, N = 28, (%) . | NHL, N = 62, (%) . | CLL, N = 28, (%) . | NHL, N = 62 (%) . | No. of patients (%) . | |
| Anemia | 4 (14) | 13 (21) | 3 (11) | 9 (15) | 29 (32) |
| Thrombocytopenia | 1 (4) | 3 (5) | 2 (7) | 10 (16) | 16 (18) |
| Diarrhea | 3 (11) | 13 (21) | 0 (0) | 0 (0) | 16 (18) |
| Petechiae | 5 (18) | 7 (11) | 1 (4) | 0 (0) | 13 (14) |
| Rash | 6 (21) | 9 (15) | 0 (0) | 1 (4) | 16 (18) |
| Pyrexia | 5 (18) | 5 (8) | 2 (7) | 0 (0) | 12 (13) |
| Nasopharyngitis | 4 (14) | 8 (13) | 0 (0) | 0 (0) | 12 (13) |
| Neutropenia | 0 (0) | 2 (3) | 4 (14) | 5 (8) | 11 (12) |
| Bruising | 6 (21) | 5 (8) | 0 (0) | 0 (0) | 11 (12) |
| Lower respiratory tract infection | 5 (18) | 1 (2) | 1 (4) | 3 (5) | 10 (11) |
| Cough | 4 (14) | 6 (10) | 0 (0) | 0 (0) | 10 (11) |
| Nausea | 2 (7) | 9 (15) | 0 (0) | 0 (0) | 11 (12) |
| Hematoma | 5 (18) | 3 (5) | 1 (4) | 0 (0) | 9 (10) |
Treatment-related AEs reported in ≥10% of patients according to treatment cohort on or before the data cutoff date of March 2, 2015.